药物重定位用于缩小良性甲状腺结节:系统综述
二甲双胍是最常评估的药物(7项研究),其中5项(包括2项RCT)报告结节体积显著缩小,但证据异质性大,需进一步大型研究确认。
要点
- 二甲双胍在多数研究中显示缩小良性甲状腺结节体积的潜力。
- 他汀类和生长抑素类似物结果不一致。
- 当前证据有限且异质性高,需大型研究验证。
核心结论
- 二甲双胍在缩小良性甲状腺结节方面显示出最一致的潜力,尤其对代谢共病患者。
- 当前证据有限且异质性大,需进一步大型研究确认疗效并指导临床使用。
研究设计与样本
- 纳入20项研究:6项随机对照试验、6项前瞻性队列、3项回顾性观察、3项病例报告、1项横断面、1项临床前研究。
- 因异质性采用叙述性综合。
主要发现
- 二甲双胍是最常评估的药物(7项研究),其中5项(包括2项RCT)报告优势结节体积显著缩小。
- 一项前瞻性研究显示最大结节直径缩小但无统计学意义,一项RCT显示干预后结节大小无变化。
- 他汀类(4项研究)和生长抑素类似物(4项研究)结果不一。
- 肌醇联合硒、草药制剂和免疫检查点抑制剂在单项研究或病例报告中显示前景。
关键数值与推荐
- 二甲双胍:7项研究,5项报告优势结节体积显著缩小(包括2项RCT)。
- 他汀类:4项研究,结果不一。
- 生长抑素类似物:4项研究,结果不一。
临床怎么用
- 对于良性甲状腺结节患者,尤其是合并代谢共病者,二甲双胍可能作为非侵入性缩小结节的潜在选择。
- 目前不推荐常规使用其他重定位药物缩小良性甲状腺结节,需个体化评估。
局限性
- 纳入研究异质性大,无法进行荟萃分析。
- 证据总体有限,多数研究样本量小或为非随机设计。
- 需要大型高质量研究确认疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Benign thyroid nodules (BTNs) are highly prevalent, and current treatment options are primarily invasive. There is a need for effective, noninvasive alternatives. OBJECTIVE: To systematically evaluate the efficacy of repurposed pharmacologic agents in reducing the size of BTNs. DATA SOURCES: MEDLINE, EMBASE, Cochrane databases, and Scopus were searched from inception to December 18, 2024. STUDY SELECTION: We included preclinical and clinical studies evaluating repurposed drugs for BTNs in adults. Of 1499 records screened, 20 studies met inclusion criteria: 6 randomized controlled trials (RCTs), 6 prospective cohorts, 3 retrospective observational studies, 3 case reports, 1 cross-sectional study, and 1 preclinical study. DATA EXTRACTION: Data were extracted independently in duplicate using a standardized form. DATA SYNTHESIS: Narrative synthesis was conducted due to heterogeneity. Metformin was the most frequently evaluated agent (7 studies), with 5 studies (including 2 RCTs) reporting statistically significant reductions in dominant nodule volume. One prospective study demonstrated a reduction in the maximum nodule diameter, which was not statistically significant, and 1 RCT showed no changes in nodule size after intervention. Statins (4 studies) and somatostatin analogues (4 studies) showed mixed results. Myo-inositol with selenium, herbal formulations, and immune checkpoint inhibitors showed promise in single studies or case reports. CONCLUSION: Metformin shows the most consistent potential for noninvasive reduction of BTN size, particularly in patients with metabolic comorbidities. However, current evidence is limited and heterogeneous. Further large-scale studies are needed to confirm efficacy and guide clinical use.
引用
- Soto Jacome C, Arce-Camposano A, Toro-Tobon D, et al. Drug Repurposing for Reducing the Size of Benign Thyroid Nodules: A Systematic Review. J Clin Endocrinol Metab. 2026. PMID: 41225692. doi:10.1210/clinem/dgaf616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。